21 results on '"Postuma R"'
Search Results
2. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder.
- Author
-
Postuma, R. B., Lang, A. E., Gagnon, J. F., Pelletier, A., and Montplaisir, J. Y.
- Subjects
- *
PARKINSONIAN disorders , *NEURODEGENERATION , *REGRESSION analysis , *DISEASE progression , *RAPID eye movement sleep , *COHORT analysis , *MEDICAL statistics - Abstract
Parkinsonism, as a gradually progressive disorder, has a prodromal interval during which neurodegeneration has begun but cardinal manifestations have not fully developed. A systematic direct assessment of this interval has never been performed. Since patients with idiopathic REM sleep behaviour disorder are at very high risk of parkinsonism, they provide a unique opportunity to observe directly the development of parkinsonism. Patients with idiopathic REM sleep behaviour disorder in an ongoing cohort study were evaluated annually with several quantitative motor measures, including the Unified Parkinson’s Disease Rating Scale, Purdue Pegboard, alternate-tap test and timed up-and-go. Patients who developed parkinsonism were identified from this cohort and matched according to age to normal controls. Their results on motor testing from the preceding years were plotted, and then assessed with regression analysis, to determine when markers first deviated from normal values. Sensitivity and specificity of quantitative motor markers for diagnosing prodromal parkinsonism were assessed. Of 78 patients, 20 developed parkinsonism. On regression analysis, the Unified Parkinson’s Disease Rating Scale first intersected normal values at an estimated 4.5 years before diagnosis. Voice and face akinesia intersected earliest (estimated prodromal interval = 9.8 years), followed by rigidity (4.4 years), gait abnormalities (4.4 years) and limb bradykinesia (4.2 years). Quantitative motor tests intersected normal values at longer prodromal intervals than subjective examination (Purdue Pegboard = 8.6 years, alternate-tap = 8.2, timed up-and-go = 6.3). Using Purdue Pegboard and the alternate-tap test, parkinsonism could be detected with 71–82% sensitivity and specificity 3 years before diagnosis, whereas a Unified Parkinson’s Disease Rating Scale score >4 identified prodromal parkinsonism with 88% sensitivity and 94% specificity 2 years before diagnosis. Removal of action tremor scores improved sensitivity to 94% and specificity to 97% at 2 years before diagnosis (cut-off >3). Although distinction between conditions was often difficult, prodromal dementia with Lewy bodies appeared to have a slower progression than Parkinson’s disease (prodromal interval = 6.0 versus 3.8 years). Using a cut-off of Unified Parkinson’s Disease Rating Scale >3 (excluding action tremor), 25% of patients with ‘still-idiopathic’ REM sleep behaviour disorder demonstrated evidence of possible prodromal parkinsonism. Therefore, using direct assessment of motor examination before parkinsonism in a REM sleep behaviour disorder, we have estimated a prodromal interval of ∼4.5 years on the Unified Parkinson’s Disease Rating Scale; other quantitative markers may detect parkinsonism earlier. Simple quantitative motor measures may be capable of reliably detecting parkinsonism, even before a clinical diagnosis can be made by experienced movement disorders neurologists. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
3. Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease.
- Author
-
Postuma, R. B., Gagnon, J. F., Vendette, M., and Montplaisir, J. Y.
- Subjects
- *
NEURODEGENERATION , *SLEEP disorders , *RAPID eye movement sleep , *PARKINSON'S disease , *BLOOD pressure , *SYMPTOMS , *EXTRAPYRAMIDAL disorders , *BRAIN diseases - Abstract
Idiopathic rapid eye movement sleep behaviour disorder is an important risk factor in the development of Parkinson's disease. Numerous potential predictive markers of Parkinson's disease may present before motor symptoms emerge, but testing of these markers in rapid eye movement sleep behaviour disorder has been performed only in small studies. There has been no comparison of markers between patients with idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease, and between men and women. We evaluated an array of potential Parkinson's disease predictive markers in 159 patients; including 68 with idiopathic rapid eye movement sleep behaviour disorder, 36 controls, 34 Parkinson's patients with rapid eye movement sleep behaviour disorder and 21 Parkinson's patients without rapid eye movement sleep behaviour disorder. Compared with controls, patients with idiopathic rapid eye movement sleep behaviour disorder demonstrated substantial olfactory loss (P < 0.001). Olfaction was more impaired in Parkinson's disease than idiopathic rapid eye movement sleep behaviour disorder and did not differ between Parkinson's patients with, or without, rapid eye movement sleep behaviour disorder. Numerous measures of motor function including the Unified Parkinson Disease Rating Scale alternate tap, Purdue Peg Board and Timed ’Up and Go‘ were impaired in idiopathic rapid eye movement sleep behaviour disorder compared with controls (P < 0.01). All of these motor measures were worse with Parkinson's disease than with idiopathic rapid eye movement sleep behaviour disorder, regardless of rapid eye movement sleep behaviour disorder status. Autonomic symptoms and systolic blood pressure drop were impaired in patients with idiopathic rapid eye movement sleep behaviour disorder compared with controls (P = 0.003). Orthostatic abnormalities in Parkinson's disease were found in the group with rapid eye movement sleep behaviour disorder (P < 0.001). However, Parkinson's patients without rapid eye movement sleep behaviour disorder were not different than controls and had less impairment than those with idiopathic rapid eye movement sleep behaviour disorder (P = 0.004) and Parkinson's patients with rapid eye movement sleep behaviour disorder (P < 0.001). Colour vision was impaired in idiopathic rapid eye movement sleep behaviour disorder compared with controls (P < 0.001). However, only Parkinson's patients with rapid eye movement sleep behaviour disorder had abnormalities significantly different than controls (P < 0.001), and there were significant differences between Parkinson's patients with or without rapid eye movement sleep behaviour disorder (P < 0.04). Idiopathic rapid eye movement sleep behaviour disorder patients had slightly increased harm avoidance scores on personality testing (P = 0.04). Other than slightly better performances among women in the Purdue Peg Board, there was no difference in any measure between men and women, suggesting similar pathogenic processes underlying rapid eye movement sleep behaviour disorder. Patients with idiopathic rapid eye movement sleep behaviour disorder demonstrate abnormalities in numerous potential markers of neurodegenerative disease—these markers are heterogeneous, generally correlate with each other and occur equally in men and women. Although these abnormalities are usually intermediate between control values and Parkinson's patients, autonomic dysfunction and colour vision appear to be more linked to rapid eye movement sleep behaviour disorder status than Parkinson's disease, suggesting a unique pathophysiology of these abnormalities. [ABSTRACT FROM PUBLISHER]
- Published
- 2009
- Full Text
- View/download PDF
4. Cognition and olfaction in Parkinson's disease.
- Author
-
Postuma R and Gagnon JF
- Published
- 2010
- Full Text
- View/download PDF
5. O.016 REM sleep behavior disorder: can you predict Parkinson's in your dreams?
- Author
-
Postuma, R.
- Published
- 2009
- Full Text
- View/download PDF
6. Trial of Prasinezumab in Early-Stage Parkinson's Disease.
- Author
-
Pagano, G., Taylor, K. I., Anzures-Cabrera, J., Marchesi, M., Simuni, T., Marek, K., Postuma, R. B., Pavese, N., Stocchi, F., Azulay, J.-P., Mollenhauer, B., López-Manzanares, L., Russell, D. S., Boyd, J. T., Nicholas, A. P., Luquin, M. R., Hauser, R. A., Gasser, T., Poewe, W., and Ricci, B.
- Abstract
BACKGROUND Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson’s disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on Parkinson’s disease. METHODS In this phase 2 trial, we randomly assigned participants with early-stage Parkinson’s disease in a 1:1:1 ratio to receive intravenous placebo or prasinezumab at a dose of 1500 mg or 4500 mg every 4 weeks for 52 weeks. The primary end point was the change from baseline to week 52 in the sum of scores on parts I, II, and III of the Movement Disorder Society–sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS; range, 0 to 236, with higher scores indicating greater impairment). Secondary end points included the dopamine transporter levels in the putamen of the hemisphere ipsilateral to the clinically more affected side of the body, as measured by 123I-ioflupane single-photon-emission computed tomography (SPECT). RESULTS A total of 316 participants were enrolled; 105 were assigned to receive placebo, 105 to receive 1500 mg of prasinezumab, and 106 to receive 4500 mg of prasinezumab. The baseline mean MDS-UPDRS scores were 32.0 in the placebo group, 31.5 in the 1500-mg group, and 30.8 in the 4500-mg group, and mean (±SE) changes from baseline to 52 weeks were 9.4±1.2 in the placebo group, 7.4±1.2 in the 1500-mg group (difference vs. placebo, –2.0; 80% confidence interval [CI], –4.2 to 0.2; P=0.24), and 8.8±1.2 in the 4500-mg group (difference vs. placebo, –0.6; 80% CI, –2.8 to 1.6; P=0.72). There was no substantial difference between the active-treatment groups and the placebo group in dopamine transporter levels on SPECT. The results for most clinical secondary end points were similar in the active-treatment groups and the placebo group. Serious adverse events occurred in 6.7% of the participants in the 1500-mg group and in 7.5% of those in the 4500-mg group; infusion reactions occurred in 19.0% and 34.0%, respectively. CONCLUSIONS Prasinezumab therapy had no meaningful effect on global or imaging measures of Parkinson’s disease progression as compared with placebo and was associated with infusion reactions. (Funded by F. Hoffmann–La Roche and Prothena Biosciences; PASADENA ClinicalTrials.gov number. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Trial of Cinpanemab in Early Parkinson's Disease.
- Author
-
Lang, A. E., Siderowf, A. D., Macklin, E. A., Poewe, W., Brooks, D. J. ., Fernandez, H. H., Rascol, O., Giladi, N., Stocchi, F., Tanner, C. M., Postuma, R. B., Simon, D. K., Tolosa, E., Mollenhauer, B., Cedarbaum, J. M., Fraser, K., Xiao, S., Evans, K. C., Graham, D. L., and Sapir, F.
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *DRUG therapy for Parkinson's disease , *RESEARCH , *NERVE tissue proteins , *ANTIPARKINSONIAN agents , *RESEARCH methodology , *EVALUATION research , *TREATMENT effectiveness , *COMPARATIVE studies , *RANDOMIZED controlled trials , *BLIND experiment - Abstract
Background: Aggregated α-synuclein plays an important role in Parkinson's disease pathogenesis. Cinpanemab, a human-derived monoclonal antibody that binds to α-synuclein, is being evaluated as a disease-modifying treatment for Parkinson's disease.Methods: In a 52-week, multicenter, double-blind, phase 2 trial, we randomly assigned, in a 2:1:2:2 ratio, participants with early Parkinson's disease to receive intravenous infusions of placebo (control) or cinpanemab at a dose of 250 mg, 1250 mg, or 3500 mg every 4 weeks, followed by an active-treatment dose-blinded extension period for up to 112 weeks. The primary end points were the changes from baseline in the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) total score (range, 0 to 236, with higher scores indicating worse performance) at weeks 52 and 72. Secondary end points included MDS-UPDRS subscale scores and striatal binding as assessed on dopamine transporter single-photon-emission computed tomography (DaT-SPECT).Results: Of the 357 enrolled participants, 100 were assigned to the control group, 55 to the 250-mg cinpanemab group, 102 to the 1250-mg group, and 100 to the 3500-mg group. The trial was stopped after the week 72 interim analysis owing to lack of efficacy. The change to week 52 in the MDS-UPDRS score was 10.8 points in the control group, 10.5 points in the 250-mg group, 11.3 points in the 1250-mg group, and 10.9 points in the 3500-mg group (adjusted mean difference vs. control, -0.3 points [95% confidence interval {CI}, -4.9 to 4.3], P = 0.90; 0.5 points [95% CI, -3.3 to 4.3], P = 0.80; and 0.1 point [95% CI, -3.8 to 4.0], P = 0.97, respectively). The adjusted mean difference at 72 weeks between participants who received cinpanemab through 72 weeks and the pooled group of those who started cinpanemab at 52 weeks was -0.9 points (95% CI, -5.6 to 3.8) for the 250-mg dose, 0.6 points (95% CI, -3.3 to 4.4) for the 1250-mg dose, and -0.8 points (95% CI, -4.6 to 3.0) for the 3500-mg dose. Results for secondary end points were similar to those for the primary end points. DaT-SPECT imaging at week 52 showed no differences between the control group and any cinpanemab group. The most common adverse events with cinpanemab were headache, nasopharyngitis, and falls.Conclusions: In participants with early Parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in DaT-SPECT imaging did not differ from those of placebo over a 52-week period. (Funded by Biogen; SPARK ClinicalTrials.gov number, NCT03318523.). [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
8. High burden of neurological disease in the older general population: results from the Canadian Longitudinal Study on Aging.
- Author
-
Wolfson, C., Fereshtehnejad, S.‐M., Pasquet, R., Postuma, R., and Keezer, M. R.
- Subjects
- *
PARKINSON'S disease , *NEUROLOGICAL disorders , *MEDICAL care , *DISEASE prevalence , *NEUROLOGY - Abstract
Background and purpose: Our objective was to study the association between the presence of a neurological disease and the comorbidity burden as well as healthcare utilization (HCU). Methods: Using baseline data from the Canadian Longitudinal Study on Aging (CLSA), we examined the burden of five neurological conditions. The CLSA is a population‐based study of approximately 50 000 individuals, aged 45–85 years at baseline. We used multivariable Poisson regression to identify correlates of comorbidity burden and HCU. Results: The lifetime prevalence of five neurological diseases is presented: epilepsy, Parkinson's disease/parkinsonism, stroke/transient ischaemic attack, multiple sclerosis and migraine. We found the somatic and psychiatric comorbidity burden to be higher in those individuals with a neurological disease (an 18–45% mean increase in the number of chronic conditions) as compared with the comparison group without a neurological disease, except for Parkinson's disease/parkinsonism. The presence of a neurological disease was associated with only a modest increase in the probability of visiting a general practitioner but was associated with a greatly increased probability of visiting a medical specialist (up to 68% more likely) or an emergency department (up to 79% more likely) and an overnight hospitalization (up to 108% more likely). Conclusions: We found striking associations between our neurological diseases and increased comorbidity burdens and HCU. These findings are important for informing public policy planning as well as driving avenues for future research. The present study established the CLSA as an important research platform for the study of neurological conditions in an aging general population. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. The GBA p.Trp378Gly mutation is a probable French‐Canadian founder mutation causing Gaucher disease and synucleinopathies.
- Author
-
Ruskey, J. A., Zhou, S., Santiago, R., Franche, L.‐A., Alam, A., Roncière, L., Spiegelman, D., Fon, E. A., Trempe, J.‐F., Kalia, L. V., Postuma, R. B., Dupre, N., Rivard, G.‐E., Assouline, S., Amato, D., and Gan‐Or, Z.
- Subjects
- *
GAUCHER'S disease , *PARKINSON'S disease , *RAPID eye movement sleep , *HAPLOTYPES , *SINGLE nucleotide polymorphisms - Abstract
Biallelic GBA mutations cause Gaucher disease (GD), and heterozygous carriers are at risk for synucleinopathies. No founder GBA mutations in French‐Canadians are known. GBA was fully sequenced using targeted next generation and Sanger sequencing in French‐Canadian Parkinson disease (PD) patients (n = 436), rapid eye movement (REM)‐sleep behavior disorder (RBD) patients (n = 189) and controls (n = 891). Haplotype, identity‐by‐descent (IBD) and principal component analyses (PCA) were performed using single nucleotide polymorphism‐chip data. Data on GD patients from Toronto and Montreal were collected from patients' files. A GBA p.Trp378Gly mutation was identified in two RBD and four PD patients (1% of all patients combined), and not in controls. The two RBD patients had converted to DLB within 3 years of their diagnosis. Haplotype, IBD and PCA analysis demonstrated that this mutation is from a single founder. Out of 167 GD patients screened, 15 (9.0%) carried the p.Trp378Gly mutation, all in trans with p.Asn370Ser. Three (20%) of the GD patients with the p.Trp378Gly mutation had developed Parkinsonism, and 11 patients had family history of PD. The p.Trp378Gly mutation is the first French‐Canadian founder GBA mutation to be described, which leads to synucleinopathies and to GD type 1 when in compound heterozygosity with p.Asn370Ser. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
10. Brain atrophy in REM sleep behavior disorder is shaped by gene expression and structural connectivity.
- Author
-
Rahayel, S., Tremblay, C., Vo, A., Lehéricy, S., Arnulf, I., Vidailhet, M., Corvol, J.-C., Study Group, I., Gagnon, J.-F., Postuma, R., Montplaisir, J., Lewis, S., Matar, E., Ehgoetz Martens, K., Borghammer, P., Knudsen, K., Monchi, O., Misic, B., and Dagher, A.
- Subjects
- *
CEREBRAL atrophy , *SLEEP disorders , *GENE expression , *RAPID eye movement sleep - Published
- 2022
- Full Text
- View/download PDF
11. Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder.
- Author
-
Chahine, L.M., Xie, S.X., Simuni, T., Tran, B., Postuma, R., Amara, A., Oertel, W.H., Iranzo, A., Scordia, C., Fullard, M., Linder, C., Purri, R., Darin, A., Rennert, L., Videnovic, A., Del Riva, P., and Weintraub, D.
- Subjects
- *
PARKINSON'S disease patients , *SLEEP disorders treatment , *SLEEP disorders , *MONTREAL Cognitive Assessment , *MULTIVARIATE analysis , *PATIENTS - Abstract
Introduction: Cognitive decline is common in Parkinson's disease (PD), and identifying patients at highest risk for it is essential. We aimed to examine the effect of possible REM sleep behavior disorder (pRBD) on rate of cognitive decline in early PD, for both global cognition and in specific cognitive domains.Methods: Parkinson's Progression Markers Initiative (PPMI) is a multi-site, international study of PD patients untreated at enrollment. pRBD was assessed with the REM sleep behavior disorder questionnaire (RBDSQ). Global cognition was assessed at baseline and annually using the Montreal Cognitive Assessment (MoCA) and a cognitive battery. Linear mixed effects models were used to examine the relationship between pRBD (RBDSQ≥6) and rate of change in cognitive variables. Age, sex, years of education, and baseline motor and cognitive scores were included as covariates.Results: The baseline sample consisted of 423 individuals with PD, mean age 61.7 years and 65.5% male. Data was available on 389, 366, and 196 participants at 1-year, 2-year, and 3-year follow-up respectively. Possible RBD occurred in 108 (25.5%) at baseline. In multivariate analyses, baseline RBD was associated with greater annual rate of decline in MoCA score (β = -0.34, 95%CI -0.54, -0.13, p < 0.001), Symbol Digit Modalities Test (β = -0.69, 95%CI -1.3, -0.09, p = 0.024), and Hopkins Verbal Learning Test-Revised, delayed free recall (β = -0.21, 95%CI -0.41, -0.013, p = 0.037).Conclusions: Possible RBD is common in early PD and predicts future cognitive decline, particularly in attention and memory domains. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
12. Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group.
- Author
-
Schenck, C H, Montplaisir, J Y, Frauscher, B, Hogl, B, Gagnon, J-F, Postuma, R, Sonka, K, Jennum, P, Partinen, M, Arnulf, I, Cochen de Cock, V, Dauvilliers, Y, Luppi, P-H, Heidbreder, A, Mayer, G, Sixel-Döring, F, Trenkwalder, C, Unger, M, Young, P, and Wing, Y K
- Abstract
Objectives: We aimed to provide a consensus statement by the International Rapid Eye Movement Sleep Behavior Disorder Study Group (IRBD-SG) on devising controlled active treatment studies in rapid eye movement sleep behavior disorder (RBD) and devising studies of neuroprotection against Parkinson disease (PD) and related neurodegeneration in RBD.Methods: The consensus statement was generated during the fourth IRBD-SG symposium in Marburg, Germany in 2011. The IRBD-SG identified essential methodologic components for a randomized trial in RBD, including potential screening and diagnostic criteria, inclusion and exclusion criteria, primary and secondary outcomes for symptomatic therapy trials (particularly for melatonin and clonazepam), and potential primary and secondary outcomes for eventual trials with disease-modifying and neuroprotective agents. The latter trials are considered urgent, given the high conversion rate from idiopathic RBD (iRBD) to Parkinsonian disorders (i.e., PD, dementia with Lewy bodies [DLB], multiple system atrophy [MSA]).Results: Six inclusion criteria were identified for symptomatic therapy and neuroprotective trials: (1) diagnosis of RBD needs to satisfy the International Classification of Sleep Disorders, second edition, (ICSD-2) criteria; (2) minimum frequency of RBD episodes should preferably be ⩾2 times weekly to allow for assessment of change; (3) if the PD-RBD target population is included, it should be in the early stages of PD defined as Hoehn and Yahr stages 1-3 in Off (untreated); (4) iRBD patients with soft neurologic dysfunction and with operational criteria established by the consensus of study investigators; (5) patients with mild cognitive impairment (MCI); and (6) optimally treated comorbid OSA. Twenty-four exclusion criteria were identified. The primary outcome measure for RBD treatment trials was determined to be the Clinical Global Impression (CGI) efficacy index, consisting of a four-point scale with a four-point side-effect scale. Assessment of video-polysomnographic (vPSG) changes holds promise but is costly and needs further elaboration. Secondary outcome measures include sleep diaries; sleepiness scales; PD sleep scale 2 (PDSS-2); serial motor examinations; cognitive indices; mood and anxiety indices; assessment of frequency of falls, gait impairment, and apathy; fatigue severity scale; and actigraphy and customized bed alarm systems. Consensus also was established for evaluating the clinical and vPSG aspects of RBD. End points for neuroprotective trials in RBD, taking lessons from research in PD, should be focused on the ultimate goal of determining the performance of disease-modifying agents. To date no compound with convincing evidence of disease-modifying or neuroprotective efficacy has been identified in PD. Nevertheless, iRBD patients are considered ideal candidates for neuroprotective studies.Conclusions: The IRBD-SG provides an important platform for developing multinational collaborative studies on RBD such as on environmental risk factors for iRBD, as recently reported in a peer-reviewed journal article, and on controlled active treatment studies for symptomatic and neuroprotective therapy that emerged during the 2011 consensus conference in Marburg, Germany, as described in our report. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
13. Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy—a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group.
- Author
-
Schenck, C.H., Montplaisir, J.Y., Frauscher, B., Hogl, B., Gagnon, J.-F., Postuma, R., Sonka, K., Jennum, P., Partinen, M., Arnulf, I., Cochen de Cock, V., Dauvilliers, Y., Luppi, P.-H., Heidbreder, A., Mayer, G., Sixel-Döring, F., Trenkwalder, C., Unger, M., Young, P., and Wing, Y.K.
- Subjects
- *
PARKINSON'S disease , *RAPID eye movement sleep , *BEHAVIOR disorders , *NEUROPROTECTIVE agents , *ACTIGRAPHY , *MILD cognitive impairment - Abstract
Abstract: Objectives: We aimed to provide a consensus statement by the International Rapid Eye Movement Sleep Behavior Disorder Study Group (IRBD-SG) on devising controlled active treatment studies in rapid eye movement sleep behavior disorder (RBD) and devising studies of neuroprotection against Parkinson disease (PD) and related neurodegeneration in RBD. Methods: The consensus statement was generated during the fourth IRBD-SG symposium in Marburg, Germany in 2011. The IRBD-SG identified essential methodologic components for a randomized trial in RBD, including potential screening and diagnostic criteria, inclusion and exclusion criteria, primary and secondary outcomes for symptomatic therapy trials (particularly for melatonin and clonazepam), and potential primary and secondary outcomes for eventual trials with disease-modifying and neuroprotective agents. The latter trials are considered urgent, given the high conversion rate from idiopathic RBD (iRBD) to Parkinsonian disorders (i.e., PD, dementia with Lewy bodies [DLB], multiple system atrophy [MSA]). Results: Six inclusion criteria were identified for symptomatic therapy and neuroprotective trials: (1) diagnosis of RBD needs to satisfy the International Classification of Sleep Disorders, second edition, (ICSD-2) criteria; (2) minimum frequency of RBD episodes should preferably be ⩾2 times weekly to allow for assessment of change; (3) if the PD-RBD target population is included, it should be in the early stages of PD defined as Hoehn and Yahr stages 1–3 in Off (untreated); (4) iRBD patients with soft neurologic dysfunction and with operational criteria established by the consensus of study investigators; (5) patients with mild cognitive impairment (MCI); and (6) optimally treated comorbid OSA. Twenty-four exclusion criteria were identified. The primary outcome measure for RBD treatment trials was determined to be the Clinical Global Impression (CGI) efficacy index, consisting of a four-point scale with a four-point side-effect scale. Assessment of video-polysomnographic (vPSG) changes holds promise but is costly and needs further elaboration. Secondary outcome measures include sleep diaries; sleepiness scales; PD sleep scale 2 (PDSS-2); serial motor examinations; cognitive indices; mood and anxiety indices; assessment of frequency of falls, gait impairment, and apathy; fatigue severity scale; and actigraphy and customized bed alarm systems. Consensus also was established for evaluating the clinical and vPSG aspects of RBD. End points for neuroprotective trials in RBD, taking lessons from research in PD, should be focused on the ultimate goal of determining the performance of disease-modifying agents. To date no compound with convincing evidence of disease-modifying or neuroprotective efficacy has been identified in PD. Nevertheless, iRBD patients are considered ideal candidates for neuroprotective studies. Conclusions: The IRBD-SG provides an important platform for developing multinational collaborative studies on RBD such as on environmental risk factors for iRBD, as recently reported in a peer-reviewed journal article, and on controlled active treatment studies for symptomatic and neuroprotective therapy that emerged during the 2011 consensus conference in Marburg, Germany, as described in our report. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
14. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease - A randomized study.
- Author
-
Rios Romenets, S, Creti, L, Fichten, C, Bailes, S, Libman, E, Pelletier, A, and Postuma, R B
- Published
- 2013
- Full Text
- View/download PDF
15. Is trauma-associated sleep disorder a sub-form REM sleep behavior disorder? a Canadian longitudinal study on aging cohort study.
- Author
-
Yao, C., Wolfson, C., Pelletier, A., and Postuma, R.
- Subjects
- *
RAPID eye movement sleep , *BEHAVIOR disorders , *SLEEP disorders , *LONGITUDINAL method , *COHORT analysis - Published
- 2019
- Full Text
- View/download PDF
16. The impact of subjective excessive daytime sleepiness on cognition in parkinson disease.
- Author
-
Rosinvil, T., Bellavance, A., Constantin, I., Rolland-Dery, M., Postuma, R., Carrier, J., and Gagnon, J.-F.
- Subjects
- *
PARKINSON'S disease , *DROWSINESS , *COGNITION , *MEMORY testing , *NEUROPSYCHOLOGICAL tests - Published
- 2019
- Full Text
- View/download PDF
17. Prevalence and associated factors for REM sleep behaviour disorder: a nation-wide population-based study of 30,097 Canadian adults.
- Author
-
Yao, C., Fereshtehnejad, S.-M., Keezer, M., Wolfson, C., Pelletier, A., and Postuma, R.
- Published
- 2017
- Full Text
- View/download PDF
18. Myoclonus as an acute complication of low-dose hydromorphone in multiple system atrophy.
- Author
-
Hofmann, A., Tangri, N., Lafontaine, A.-L., and Postuma, R. B.
- Subjects
- *
LETTERS to the editor , *MYOCLONUS - Abstract
A letter to the editor is presented about a case of 75-year-old man who experienced myoclonus as an acute complication of low-dose hydromorphone in multiple system atrophy in the August 2006 issue.
- Published
- 2006
- Full Text
- View/download PDF
19. Corrigendum to “Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy—a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group” [Sleep Med 14(8) (2013) 795–806].
- Author
-
Schenck, C.H., Montplaisir, J.Y., Frauscher, B., Hogl, B., Gagnon, J.-F., Postuma, R., Sonka, K., Jennum, P., Partinen, M., Arnulf, I., de Cock, V. Cochen, Dauvilliers, Y., Luppi, P.-H., Heidbreder, A., Mayer, G., Sixel-Döring, F., Trenkwalder, C., Unger, M., Young, P., and Wing, Y.K.
- Published
- 2014
- Full Text
- View/download PDF
20. Patterns of cortical thinning in idiopathic rapid eye movement sleep behavior disorder.
- Author
-
Rahayel, S., Montplaisir, J., Monchi, O., Bedetti, C., Postuma, R., and Gagnon, J.
- Subjects
- *
RAPID eye movement sleep , *EYE movements , *SLEEP disorders , *SOLID solutions , *SOLUTION (Chemistry) , *SEPARATION (Technology) , *SLEEP stages , *SYNUCLEINS - Abstract
Introduction: Rapid eye movement sleep behavior disorder (RBD) is a parasomnia considered as a risk factor for synucleinopathies, such as Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). We investigated gray matter thickness, gray matter density, and white matter integrity in idiopathic RBD (iRBD) patients using corticometry, voxel-based morphometry (VBM), and diffusion tensor imaging (DTI), respectively. Materials and methods: Twenty patients with polysomnography-confirmed iRBD (mean age, 64.2±7.0; 20 men) and 42 age- and gender-matched healthy controls (mean age, 63.2±7.3, 28 men) underwent a 3T structural and diffusion MRI examination. Corticometry, VBM, and DTI data were analyzed respectively using both the CIVET pipeline for minctools and the SurfStat toolbox for MATLAB, FSL-VBM, and Tract-Based Spatial Statistics (TBSS) in FSL. For the corticometry and VBM analyses, age and gender were covaried out, whereas only age was used for DTI analyses. Results: Several regions of the brain presented with decreased cortical thickness in iRBD patients compared to the controls, mainly in the frontal cortex (i.e., gyrus rectus, orbitofrontal cortex, superior frontal gyrus, supplementary motor area), the cingulate and paracingulate cortices, the precuneus, and the lingual and fusiform gyri. As regards gray matter density and white matter integrity, no significant differences between groups were found. Conclusion: iRBD patients have structural alterations in gray matter thickness, mainly in the frontal and cingulate cortices, the precuneus, and the fusiform and lingual gyri. Corticometry appears to be more sensitive than traditional VBM for visualizing gray matter alterations in iRBD patients. The pattern of cortical gray matter abnormalities found in iRBD patients shares several similarities with that found in PD and DLB. Acknowledgements: The study was supported by grants from the Canadian Institutes of Health Research and the Fonds de Recherche du Québec – Santé. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
21. Le test d’immobilisation suggérée pour le diagnostic de syndrome des jambes sans repos au cours de la maladie de Parkinson
- Author
-
Cochen de Cock, V., Bayard, S., Yu, H., Grini, M., Carlander, B., Postuma, R., Charif, M., and Dauvilliers, Y.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.